Moreover, EGFR expression in tumors has been associated with a poor response to therapy, development of cytotoxic drug resistance, disease progression, and poor survival.
Ngaphezu kwalokho, ukubonakaliswa kwe-EGFR kumathumba kuhlotshaniswe nempendulo engeyinhle ekwelashweni, ukuthuthukiswa kokumelana nomuthi we-cytotoxic, ukuqhubeka kwezifo, nokusinda okuncane.